Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267725 | 0.83 | L3MBTL1 (0.44) | L3MBTL1ADORA1ATMHTTUSP2 | |
| SCHEMBL14999156 | 0.80 | L3MBTL1 (0.44) | L3MBTL1ADORA1ATMHTTUSP2 | |
| SCHEMBL3996113 | 0.80 | PARP2 (0.45) | L3MBTL1ADORA1CA2HTTALDH1A1 | |
| SCHEMBL29193696 | 0.80 | CA2 (0.42) | L3MBTL1ADORA1CA12CA1CA2 | |
| SCHEMBL4170301 | 0.78 | ATM (0.42) | L3MBTL1ADORA1ATMHTTUSP2 | |
| SCHEMBL2494002 | 0.71 | RAB9A (0.59) | L3MBTL1ATMHTTALDH1A1MAPT | |
| SCHEMBL3211414 | 0.71 | XIAP (0.59) | L3MBTL1ADORA1POLBHDAC3HDAC1 | |
| SCHEMBL17857141 | 0.69 | L3MBTL1 (0.47) | L3MBTL1ADORA1CA12CA1CA2 | |
| SCHEMBL14667369 | 0.68 | L3MBTL1 (0.41) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL1661669 | 0.68 | KMT2A (0.47) | L3MBTL1ADORA1HTTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9732073-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160102084-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-9248190-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140314785-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8815848-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | L3MBTL1 3398/4885NOS3 613/4885NOS1 2362/4885 |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | L3MBTL1 3398/4885NOS3 613/4885NOS1 2362/4885 |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | L3MBTL1 4806/4885NOS3 759/4885NOS1 1165/4885 |
| US-20140314785-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | L3MBTL1 3398/4885NOS3 613/4885NOS1 2362/4885 |
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | L3MBTL1 3398/4885NOS3 613/4885NOS1 2362/4885 |
| US-20160102084-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | L3MBTL1 3398/4885NOS3 613/4885NOS1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.